In Vivo CAR-T Engineering Could Make Cancer Cell Therapy Cheaper, Faster and More Accessible
A review of how viral and non-viral vectors can turn a patient's own T cells into CAR-T cells inside the body, skipping costly ex vivo manufacturing.
Resumo
Approved CAR-T therapies are made outside the body from each patient's own T cells. This is slow, costly and logistically hard, and it requires lymphodepleting chemotherapy. This review examines in vivo CAR-T engineering, where a vector injected into the patient reprograms T cells inside the body. The authors compare viral platforms (lentiviruses, γ-retroviruses, AAV, viral-like particles) and non-viral platforms (lipid nanoparticles, polymers). They focus on how surface engineering, envelope protein choice and targeting ligands steer vectors to T cells. Early preclinical data show selective T cell transduction and tumor or B cell clearance in humanized mice. First-in-human reports now exist in myeloma and lupus. Key hurdles remain: vector stability, T cell specificity, immunogenicity, and unproven cost claims.
Resumo Detalhado
Why it matters: CAR-T therapy has transformed treatment of blood cancers, but every approved product is made ex vivo. T cells are collected, engineered, expanded and reinfused. The process takes weeks, products have limited shelf life, patients usually need lymphodepleting chemotherapy, and costs are very high. In vivo CAR-T engineering aims to reprogram a patient's own T cells inside the body with an injectable vector, which could make the therapy simpler and more scalable.
What was reviewed: This is a narrative review, not a new experiment. It surveys delivery platforms (lentiviruses, γ-retroviruses, adeno-associated viruses, viral-like particles, lipid nanoparticles and polymer carriers) and the design principles behind them: vector tropism, membrane modification, envelope protein selection and targeting ligands. It also covers preclinical and early clinical work. The portion of the text available for this summary covers the viral platforms in detail. The non-viral sections are described only in the abstract.
Key points: Lentiviruses are the most widely used platform because they integrate large payloads and transduce non-dividing cells. In humanized mouse models, lentiviruses targeted with CD8, CD4 or CD3 binders achieved selective T cell transduction and B cell depletion. For example, CD4-targeted vectors produced CAR expression in 40–60% of CD4+ cells. The VivoVec system adds a rapamycin-inducible cytokine receptor to support transduced cells. Targeting is achieved by displaying scFvs on the viral envelope, bridging antibodies, or click-chemistry conjugation. scFv display is the most common approach because it is simple and low in immunogenicity, but it can lower viral titers. Standard VSV-G envelopes are broadly tropic and vulnerable to serum complement. Cocal glycoprotein offers similar titers with better serum resistance and is used in clinical-stage VivoVec products. Nipah virus-based envelopes are also being explored. They fuse directly at the plasma membrane and face low pre-existing immunity. AAV and viral-like particles are less developed for CAR delivery. Viral-like particles can give transient CAR mRNA expression, which may improve safety.
Implications: Because the approach uses minimally manipulated cells in situ, expansion may be more gradual, with less exhaustion and a more stem-like phenotype. Avoiding lymphodepletion could reduce infection risk and preserve immune function, possibly allowing epitope spreading. First-in-human reports have emerged for relapsed or refractory multiple myeloma and refractory lupus. One CEO has suggested doses could cost about $5,000.
Caveats: The authors note that cost projections are speculative and unvalidated. Lymphodepletion still helps in current protocols. High tumor burden raises the risk of severe cytokine release syndrome, neurotoxicity and early exhaustion. An intact immune system may attack the vector. Off-target transduction, especially of tumor cells, could cause antigen masking and immune evasion. Most evidence comes from humanized mouse models, so durability, safety and efficacy in people remain to be shown.
Principais Descobertas
- Surface-engineered lentiviral vectors and lipid nanoparticles are the most advanced in vivo CAR-T platforms, with first-in-human reports in myeloma and lupus.
- CD4-targeted lentiviral vectors drove CAR expression in 40–60% of CD4+ T cells in humanized mice, sparing CD8+ cells and clearing B cells.
- Cocal glycoprotein pseudotyping gives titers similar to VSV-G with better human serum resistance, and is used in clinical-stage VivoVec products.
- Viral-like particles deliver CAR mRNA transiently to T cells, avoiding genomic integration, and controlled lymphoma in humanized mice.
- Key unresolved challenges are T cell specificity, vector immunogenicity, stability and the unproven cost-reduction claims such as roughly $5,000 per dose.
Metodologia
Narrative review of preclinical and early clinical literature on in vivo CAR-T delivery. It compares viral and non-viral vectors by targeting strategy, envelope choice, efficacy, immunogenicity and safety. No systematic search methodology or quantitative synthesis is described in the available text.
Limitações do Estudo
This is a narrative review, and the supplied text ends partway through the viral envelope section, so the non-viral and clinical sections could not be assessed in detail. Most cited efficacy data come from humanized mouse models, and cost and safety advantages are largely theoretical. Human data on durability, vector immunogenicity, off-target transduction and long-term safety are still scarce.
Gostou deste resumo?
Receba as pesquisas de longevidade mais recentes na sua caixa de entrada toda semana.
Digite seu e-mail para assinar: